Navigation Links
WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008
Date:5/27/2008

OAKLAND, Calif., May 27 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT, TSX: WHT) -- World Heart Corporation (the "Company") today announced that on May 20, 2008, it had received a letter from the NASDAQ Hearings Panel stating that they had received the Company's request to appeal the NASDAQ Listing Qualification Staff determination to delist World Heart Corporation's securities from the NASDAQ Stock Market. Accordingly, the delisting action referenced in the NASDAQ Staff's determination letter has been stayed, pending a final written decision by the NASDAQ Hearings Panel.

This letter provided formal notice that the panel will consider our appeal at an oral/written hearing. The hearing will be held on Thursday, July 10, 2008, at 2:30 PM in Washington, DC.

This decision by the NASDAQ Hearings Panel means that the stock will continue to trade at least until the determination is made at this hearing.

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems. The Company is headquartered in Oakland, California, USA with additional facilities in Salt Lake City, Utah and Herkenbosch, Netherlands. WorldHeart's registered office is Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include any statements regarding the Company's ability to regain compliance with the NASDAQ Capital Market listing requirements, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: the Company's immediate need for additional capital, risks in product dev
'/>"/>

SOURCE World Heart Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
2. WorldHeart 10-KSB Audit Report Includes Going Concern Qualification
3. WorldHeart Schedules Teleconference
4. AMICAS Announces Integrations at More Than 100 MEDITECH Facilities
5. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
6. Epitomics Announces the Creation of 1000th Rabbit Monoclonal Antibody
7. NicOx Announces Departure of Damian Marron for CEO Position
8. CellCyte Genetics Corporation Announces Launch of Comprehensive Web site Powered by PRNewswire Investor Room Backend Technology
9. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
10. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
11. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group finds that the vascular ... Russia , India and ... 2013, roughly equal to the size of the United ... market will experience much faster growth as a result of strong ... Other key findings from Decision Resources Group,s coverage of the ...
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient ... its myPROpad™ ePRO tablet with the addition of a ... most widely used and well-respected Patient Reported Outcome (PRO) ... is used during clinical trials and in other health ... used to demonstrate Health-Related Quality of Life outcomes (HRQoL) ...
(Date:8/19/2014)... 19, 2014 Shimadzu Scientific Instruments ... Prominence-i and Nexera-i, adding to the company’s extensive ... functionality, an intuitive operating environment, and full automation, ... efficient workflow for conventional to ultra-high-speed analysis. ... and intelligent design so users can begin building ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3
... 10, 2011 Verenium Corporation (Nasdaq: VRNM ... development and commercialization of high-performance enzymes, today reported a ... the third quarter and nine months ended September 30, ... operational progress in the first nine months of this ...
... Science (Tianjin) Co. Ltd., a leading research-based contract manufacturer of ... sites in the U.S. and China, was pleased to receive ... and manufacturing facility on the afternoon of October 24th, 2011. ... Political Bureau of the CPC Central Committee and Premier of ...
... UV Flu Technologies, Inc. ( OTCBB: UVFT ... has expanded its International Distribution by adding representation in Oman, ... the Company,s Distributor in India, Ormed Systems, a leader in ... other parts of the world. The Company continues efforts in ...
Cached Biology Technology:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 2Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 3Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 4Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 5Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 6Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 7Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 8Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 9Premier Wen Visits Asymchem's Tianjin Facility 2UV Flu Technologies Expands Its International Footprint 2UV Flu Technologies Expands Its International Footprint 3
(Date:8/19/2014)... caesarean section rate, suggests a new commentary published today ... Obstetrics and Gynaecology (BJOG) . , China has one ... Of 16 million babies born in 2010, approximately half ... known, the current Chinese language literature on caesarean rates ... to 58%. However, before the 1980s, the caesarean rate ...
(Date:8/19/2014)... It,s not a lemur. It,s not an African Bush Baby ... tiny, adorable and downright "cool" primate from Southeast Asia. , ... with," said Rafe Brown, curator-in-charge at the University of Kansas, ... extremely cute, furry body; a long tail with a furry ... tips that look a bit like the disks on the ...
(Date:8/19/2014)... Some infants born with neonatal abstinence syndrome ... more difficult time going through withdrawal than others, ... While genetic and epigenetic (when genes are turned ... as potential factors, researchers at Boston University School ... conducted a first of its kind study to ...
Breaking Biology News(10 mins):Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2
... this weeks PLoS Medicine, researchers have found that more ... infectious eye disease trachoma. Six million people most ... the developing world are blind because of the ... that multiple strains of the Chlamydiceae family of bacteria ...
... Hydrogen peroxide, the same mild acid that many people use ... also produced by the body to keep cells healthy. Now, ... how part of this complex process works. Reporting ... by W. Todd Lowther, Ph.D., developed a three-dimensional snapshot of ...
... coalition of 17 organizations, including the National Academy ... the National Science Teachers Association, is calling on ... the promotion of science education, including evolution. According ... issue of The FASEB Journal, the introduction of ...
Cached Biology News:Multiple species of bacteria may cause trachoma: Implications for treatment 2Research explores role of hydrogen peroxide in cell health 2Evolution education is a 'must' says coalition of scientific and teaching organizations 2
Rac 1/2/3/4 (S-18)...
... Recognizes K+ Cl- ... shows no significant sequence ... or CCC.,SPECIES REACTIVITIES: The ... conserved in human, mouse, ...
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
Mouse monoclonal [DAPK-55] to DAP Kinase 1 ( Abpromise for all tested applications). entrezGeneID: 1612 SwissProtID: P53355...
Biology Products: